Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group reported a decline in 2025 revenue to RMB26.0 billion, with finished drugs falling double digits, while bulk products and functional foods posted modest growth. Reported profit attributable to shareholders slipped to RMB3.88 billion and underlying profit dropped more sharply, yet the board raised the full-year dividend by 11.5% and continued share buy-backs, signalling confidence in cash flow and long-term prospects.
Management framed 2025 as a transition year for China’s pharmaceutical sector, as regulators deepened reforms and shifted emphasis from scale to innovation, resulting in a record 76 innovative drugs approved nationwide. New supportive policies for innovative drugs and ongoing optimisation of national drug procurement are expected to encourage R&D investment, ensure supply and quality, and curb irrational competition, providing a more favourable framework for CSPC’s innovation-led strategy.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company focused on finished drugs, bulk pharmaceutical products, and functional foods and related products. The group operates mainly in the Chinese healthcare market, where it is positioned to benefit from the country’s push toward value-driven innovation and high-quality development in innovative drugs.
Average Trading Volume: 110,368,095
Technical Sentiment Signal: Buy
Current Market Cap: HK$95.13B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.